Ardelyx

Ardelyx, Inc. is a biopharmaceutical company. engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ardelyx reports strong Q4 earnings, poised for product expansion

Ardelyx's Q4 performance reflects revenue growth, improved financial efficiency, and progress towards expanding its product portfolio.
While facing challenges such as regulatory processes and market competition, Ardelyx's strengths lie in successful product launches and a proactive commercial strategy.
Opportunities for Ardelyx include leveraging positive feedback for XPHOZAH, raising additional funds for growth, and diversifying revenue through new product launches.

Ardelyx reports sales growth, readies XPHOZAH launch amid challenges

Ardelyx showed strong sales growth for IBSRELA and is poised for the XPHOZAH launch
Financially, the company raised significant funds and maintains a healthy cash position
Challenges include managing expenses and improving profitability amidst losses
Opportunities lie in upcoming product launches and optimizing financial operations

Ardelyx reports strong Q2 performance amidst legislative challenges and growth opportunities

Ardelyx's Q2 performance reflects growth in IBSRELA sales and overall revenue, despite incurring a net loss.
The company faces challenges from pending legislation and financial burdens related to XPHOZAH launch preparation.
Opportunities lie in the potential of XPHOZAH launch, market reception of IBSRELA, and addressing legislative impacts.

Ardelyx reports strong Q3 earnings, poised for successful XPHOZAH launch

Ardelyx's Q3 performance reflects financial strength and positive market reception for IBSRELA.
Challenges in pricing strategy and market competition require strategic planning for XPHOZAH's launch.
Opportunities lie in leveraging financial stability, physician interest, and promotional activities for XPHOZAH success.
The company's commitment to patient access and learnings from IBSRELA will drive future growth and market penetration.

Ardelyx reports strong revenue growth driven by IBSRELA success

Ardelyx is strategically investing in growth, focusing on sustaining momentum for its products. The company is well-resourced and optimistic about the future performance of IBSRELA and XPHOZAH. Despite challenges in operating expenses, Ardelyx remains committed to its commercialization efforts.

Ardelyx reports robust Q1 performance driven by XPHOZAH success

Ardelyx's Q1 2024 earnings call showcased strong revenue growth, particularly driven by XPHOZAH and IBSRELA. The company's cash position remains healthy, and there is a clear focus on expanding market reach and driving adoption of key therapies.

Ardelyx reports robust Q2 earnings, focuses on patient access advocacy

Ardelyx's Q2 2024 performance reflects strong revenue growth driven by IBSRELA and XPHOZAH, with a focus on shareholder value and patient access advocacy. While facing challenges in legal battles and expense management, the company is poised to capitalize on opportunities through sales force expansion and market differentiation strategies.

Ardelyx (ARDX) reports robust Q3 earnings, navigates Medicare coverage challenges

Ardelyx's Q3 earnings call highlighted strong financial performance, success of key medications, and strategies to address Medicare coverage challenges. The company's focus on patient access, commitment to therapy availability, and positive market impact showcase its growth potential and resilience in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan

Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021

Ardelyx (ARDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Ardelyx (ARDX) Stock Jumps 6.8%: Will It Continue to Soar?

Ardelyx Announces Poster Presentations, Educational Symposium, and Exhibitor Showcase at National Kidney Foundation 2021 Virtual Spring Clinical Meetings

Calumet Inc

Babcock & Wilcox Enterprises

Leaf Group Ltd

Pacific Mercantile Bancorp

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Sizzling Stocks to Buy Under $10 With Sizable Upside Potential

Ardelyx Appoints Muna Bhanji, R.Ph, to its Board of Directors

MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Knight has the exclusive right to commercialize IBSRELA in Canada under the terms of a license agreement entered into with Ardelyx, Inc. (NASDAQ: ARDX) in March 2018, which license agreement also provides Knight with exclusive rights to commercialize tenapanor for hyperphosphatemia in Canada.   IBSRELA was approved by Health Canada on April 15, 2020 and is now covered by most private insurance companies in Canada.

Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ - New Innovative Treatment for Irritable Bowel Syndrome with Constipation

Ardelyx has a PDUFA on April 29 for tenapanor in hyperphosphatemia in CKD patients. Data has been good, and there's an unmet medical need.

Ardelyx Before The April PDUFA

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

FREMONT, Calif., Feb. 17, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab, president and chief...

Ardelyx to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Avis Budget Group

Cannae Hlds

Multiplan Corp

Silverback Therapeutics

Seer

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there has been as the pandemic worsens.

Notable Insider Buys Of the Past Week: Avis Budget, Biotech IPOs And More

FREMONT, Calif., Nov. 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that it will hold a virtual Analyst Day on...

Ardelyx to Webcast Virtual Analyst Day

Will Ardelyx (ARDX) Report Negative Q3 Earnings? What You Should Know

I last wrote about Ardelyx as the company was close to submitting its tenapanor NDA and the stock was trading for over $8. Since that time, Ardelyx had gotten its NDA accepted with an April 29, 2021 PDUFA date, yet the stock has dropped to about $5.

Ardelyx Is An Even Bigger Value After Recent Sell-Off

FREMONT, Calif. and TOKYO, Oct. 22, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company developing targeted, first-in-class medicines to improve the lives of patients with kidney and cardiovascular diseases, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151)...

Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020

FREMONT, Calif., Oct. 12, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that five abstracts on tenapanor have been...

Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020

Ardelyx Inc. (NASDAQ: ARDX) shares dipped on Tuesday after the firm posted a win with the U.S.

Why This FDA Win for Ardelyx Is Definitely a ‘Sell the News’ Moment

Giving The 'Thumbs Up' On Ardelyx

FREMONT, Calif., Aug. 3, 2020 /PRNewswire/ -- Ardelyx, Inc.

Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor

FREMONT, Calif., June 8, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Justin...

Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer

Ardelyx: Sales Estimates For Tenapanor Suggest Upside In The Stock

FREMONT, Calif., May 21, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that on May 18, 2020, the...

Ardelyx Reports Inducement Grants  Under Nasdaq Listing Rule 5635(c)(4)

FREMONT, Calif., May 18, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Susan...

Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer

As of late, it has definitely been a great time to be an investor Ardelyx

Will Ardelyx Continue to Surge Higher?

Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

News for Ardelyx Stock (ARDX)